Ellen Cavaleri
Contatto Relazioni con gli Investitori presso LYRA THERAPEUTICS, INC.
Posizioni attive di Ellen Cavaleri
Società | Posizione | Inizio | Fine |
---|---|---|---|
LYRA THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/01/2022 | - |
Public Communications Contact | 01/01/2022 | - |
Storia della carriera di Ellen Cavaleri
Precedenti posizioni note di Ellen Cavaleri
Società | Posizione | Inizio | Fine |
---|---|---|---|
KADMON HOLDINGS, INC. | Contatto Relazioni con gli Investitori | - | - |
Formazione di Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Investor Relations Contact | 2 |
Public Communications Contact | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Ellen Cavaleri
- Esperienza